Status:
RECRUITING
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
Lead Sponsor:
Tempus AI
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care t...
Eligibility Criteria
Inclusion
- Known or suspected colorectal adenocarcinoma (Stage I to IVA disease)
- Planning to undergo or has undergone a surgical resection for suspected adenocarcinoma of the colon or rectum with curative intent.
- 18 years old or older
- Willing and able to provide informed consent
- Willing to have additional blood samples collected during routine surveillance visits
Exclusion
- Not willing to have additional blood samples collected
- Pathology that is not consistent with colorectal adenocarcinoma
Key Trial Info
Start Date :
June 21 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2029
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05234177
Start Date
June 21 2022
End Date
February 1 2029
Last Update
May 6 2025
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Mercy Clinic Oncology - Fort Smith
Fort Smith, Arkansas, United States, 72903
2
MemorialCare
Fountain Valley, California, United States, 92708
3
The Center for Cancer and Blood Disorders
Bethesda, Maryland, United States, 20817
4
Mercy Clinic Oncology and Hematology - Joplin
Joplin, Missouri, United States, 64804